Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. FDA’s Response To Heparin Scare Made With “Alacrity And Sound Judgment” – von Eschenbach

This article was originally published in PharmAsia News

Executive Summary

In a Feb. 15 e-mail to agency personnel, U.S. FDA Commissioner Andrew von Eschenbach said the U.S. FDA has responded to the recent import safety scare related to Baxter Healthcare's injectable heparin "with its customary alacrity and sound judgment.

You may also be interested in...



U.S. FDA Move “Beyond Our Borders” Begins With China

Congressional concerns over inspection oversight in the midst of a heparin safety scare have not dampened FDA's efforts to highlight its new overseas initiative, "FDA Beyond Our Borders.

U.S. FDA Move “Beyond Our Borders” Begins With China

Congressional concerns over inspection oversight in the midst of a heparin safety scare have not dampened FDA's efforts to highlight its new overseas initiative, "FDA Beyond Our Borders.

China State FDA Issues Warning In Wake Of Heparin Safety Concerns

SHANGHAI - In the wake of a U.S. safety scare related to Baxter Healthcare's heparin, China's State FDA has warned foreign pharmaceutical companies to conduct business with only licensed Chinese companies

Related Content

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel